Genmab A/S (GMAB)Healthcare | Biotechnology | Copenhagen, Denmark | NasdaqGS
28.55 USD
+0.25
(0.883%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 28.55 Short-term: ★★★☆☆ | Long-term: ★★★★☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 19, 2026, 12:51 a.m. EDT
Genmab is a high-conviction mid-cycle turnaround play. Despite earnings misses (-94% growth), the balance sheet remains solvent, the backlog ($3.96B DARZALEX) is robust, and institutional support has stabilized (Deutsche Bank upgrade, herd of 'Buy' recommendations). The options market has priced in a range with a distinct bias toward upside momentum over the next 6-12 months, betting on pipeline readouts. For long-term investors, the risk-reward is favorable, but for short-term traders, expect increased volatility as the market digests earnings and upcoming data, with the fair value floor holding around $30 while upside targets remain near $38. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.181585 |
| AutoTheta | 0.187463 |
| AutoETS | 0.187736 |
| AutoARIMA | 0.187739 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 51% |
| H-stat | 3.71 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.342 |
| Excess Kurtosis | -0.37 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 92.8 |
| Revenue per Share | 5.9854 |
| Market Cap | 17,527,146,496 |
| Trailing P/E | 18.54 |
| Forward P/E | 16.15 |
| Beta | 0.74 |
| Profit Margins | 25.89% |
| Website | https://www.genmab.com |
As of April 19, 2026, 12:51 a.m. EDT: Near-term (April) options show elevated IV (1.49% for 25-strike puts) and high OI for puts below current price, suggesting ahedged floor or defined risk positions. However, June-August calls show a significant buildup of Open Interest (OI) at $20M (35-40 strikes, 1000+) representing a clear upside skew. Notably, $35 and $40 calls for Dec 2026 and Jan 2027 show 'New Flow' where volume vastly exceeds Open Interest, indicating fresh speculative demand betting on upside momentum. The price has recovered from lows (~$26 on March 30) to current levels (~$29), aligning with the call buying pressure.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.42252123 |
| Address1 | Carl Jacobsens Vej 30 |
| Address2 | Valby |
| All Time High | 103.19 |
| All Time Low | 0.654 |
| Ask | 36.44 |
| Ask Size | 2 |
| Average Analyst Rating | 1.5 - Buy |
| Average Daily Volume10 Day | 1,685,890 |
| Average Daily Volume3 Month | 1,625,250 |
| Average Volume | 1,625,250 |
| Average Volume10Days | 1,685,890 |
| Beta | 0.742 |
| Bid | 20.73 |
| Bid Size | 2 |
| Book Value | 9.489 |
| City | Copenhagen |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | Denmark |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 28.55 |
| Current Ratio | 2.022 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 28.86 |
| Day Low | 28.395 |
| Debt To Equity | 92.8 |
| Earnings Call Timestamp End | 1,771,347,600 |
| Earnings Call Timestamp Start | 1,771,347,600 |
| Earnings Growth | -0.944 |
| Earnings Quarterly Growth | -0.946 |
| Earnings Timestamp | 1,778,184,000 |
| Earnings Timestamp End | 1,778,184,000 |
| Earnings Timestamp Start | 1,778,184,000 |
| Ebitda | 1,290,000,000 |
| Ebitda Margins | 0.34677 |
| Enterprise To Ebitda | 4.24 |
| Enterprise To Revenue | 1.47 |
| Enterprise Value | 5,470,222,336 |
| Eps Current Year | 1.08486 |
| Eps Forward | 1.7679 |
| Eps Trailing Twelve Months | 1.54 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 28.05 |
| Fifty Day Average Change | 0.5 |
| Fifty Day Average Change Percent | 0.017825313 |
| Fifty Two Week Change Percent | 42.252125 |
| Fifty Two Week High | 35.43 |
| Fifty Two Week High Change | -6.880001 |
| Fifty Two Week High Change Percent | -0.19418575 |
| Fifty Two Week Low | 18.885 |
| Fifty Two Week Low Change | 9.664999 |
| Fifty Two Week Low Change Percent | 0.51178175 |
| Fifty Two Week Range | 18.885 - 35.43 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,243,863,000,000 |
| Float Shares | 60,889,434 |
| Forward Eps | 1.7679 |
| Forward P E | 16.149103 |
| Free Cashflow | 1,068,124,992 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 2,973 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.93601996 |
| Gross Profits | 3,481,999,872 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0 |
| Held Percent Institutions | 0.121020004 |
| Implied Shares Outstanding | 613,910,580 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ir Website | http://ir.genmab.com/index.cfm |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,525,132,800 |
| Last Split Factor | 5:1 |
| Long Business Summary | Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1059, GEN1055, and GEN1057 for solid tumors; and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Medarex, Inc., Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Novo Nordisk A/S, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark. |
| Long Name | Genmab A/S |
| Market | us_market |
| Market Cap | 17,527,146,496 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_665704 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | 963,000,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 17,458,768,124 |
| Number Of Analyst Opinions | 11 |
| Open | 28.8 |
| Operating Cashflow | 1,186,000,000 |
| Operating Margins | 0.22968 |
| Payout Ratio | 0.0 |
| Peg Ratio | 1.79 |
| Phone | 45 70 20 27 28 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 28.55 |
| Post Market Time | 1,776,462,714 |
| Previous Close | 28.3 |
| Price Eps Current Year | 26.31676 |
| Price Hint | 2 |
| Price To Book | 3.0087469 |
| Price To Sales Trailing12 Months | 4.7115984 |
| Profit Margins | 0.25887 |
| Quick Ratio | 2.009 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.54545 |
| Region | US |
| Regular Market Change | 0.25 |
| Regular Market Change Percent | 0.883392 |
| Regular Market Day High | 28.86 |
| Regular Market Day Low | 28.395 |
| Regular Market Day Range | 28.395 - 28.86 |
| Regular Market Open | 28.8 |
| Regular Market Previous Close | 28.3 |
| Regular Market Price | 28.55 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 1,898,586 |
| Return On Assets | 0.08101 |
| Return On Equity | 0.17535 |
| Revenue Growth | 0.03 |
| Revenue Per Share | 5.9854 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 613,910,580 |
| Shares Percent Shares Out | 0.0139999995 |
| Shares Short | 8,576,449 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 8,699,348 |
| Short Name | Genmab A/S |
| Short Percent Of Float | 0.014099999 |
| Short Ratio | 5.26 |
| Source Interval | 15 |
| Symbol | GMAB |
| Target High Price | 48.0 |
| Target Low Price | 24.5 |
| Target Mean Price | 37.13636 |
| Target Median Price | 38.5 |
| Total Cash | 1,715,000,064 |
| Total Cash Per Share | 27.832 |
| Total Debt | 5,425,999,872 |
| Total Revenue | 3,720,000,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 1.54 |
| Trailing P E | 18.538961 |
| Trailing Peg Ratio | 1.7863 |
| Triggerable | 1 |
| Two Hundred Day Average | 28.50105 |
| Two Hundred Day Average Change | 0.048948288 |
| Two Hundred Day Average Change Percent | 0.0017174204 |
| Type Disp | Equity |
| Volume | 1,898,586 |
| Website | https://www.genmab.com |
| Zip | 2,500 |